• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Elevai Labs Inc.

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    SC 13G 1 l1cap_13g.htm SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Elevai Labs Inc.  
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    28622K 203
    (CUSIP Number)
     
    September 24, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

     

     

    CUSIP No.  28622K 203   13G   Page 2 of 5 Pages

     

    1  NAME OF REPORTING PERSONS
       
      L1 Capital Global Opportunities Master Fund, Ltd.
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands 
      5                  SOLE VOTING POWER
         
          3,171,061 (1)(2)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH    3,171,061 (1)(2)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
       3,171,061 (1)(2)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
       9.99% (1)(2)
    12 TYPE OF REPORTING PERSON
     

     

    FI (3)

           

     

    (1)   On September 24, 2024, the Reporting Person purchased 700,000 shares of the Issuer’s Common Stock, and 5,714,285 each of Series A Warrants and Series B Warrants in a public offering; in that same public offering, it also purchased 5,014,285 Pre-Funded Warrants. The aggregate amount beneficially owned as set forth above represents 433,334 shares of Common Stock previously acquired by the Reporting Person, its purchase of 700,000 shares of the Issuer’s Common Stock and its beneficial ownership of 2,037,727 shares of the Issuer’s Common Stock issuable upon the exercise of the Series A Warrants, which are subject to a 9.99% beneficial ownership limitation. Does not include 5,014,285 shares of the Issuer’s Common Stock underlying Pre-Funded Warrants, which are subject to a 4.99% beneficial ownership limitation, 3,676,558 shares of the Issuer’s Common Stock issuable upon the exercise of Series A Warrants, which are subject to a 9.99% beneficial ownership limitation, or 5,714,285 shares of Common Stock underlying Series B Warrants, which are subject to a 9.99% beneficial ownership limitation. The Series A Warrants and Series B Warrants are exercisable beginning on the Shareholder Approval Date as defined therein, and this Schedule 13G assumes such date will occur within 60 days following September 24, 2024, the closing date of the public offering, since according to the Issuer’s Current Report on Form 8-K filed on September 25, 2024, the Issuer has obtained the shareholder approval as of that date. The Warrants referred to above are subject to certain adjustments, including the potential reduction to the exercise price and increase in underlying shares of Common Stock issuable upon exercise thereof, and the share amounts set forth above do not give effect to such adjustments.

     

    (2)   Based on 29,704,614 shares of Common Stock outstanding upon the closing of an offering based upon the pre-offering shares outstanding as disclosed in the Issuer’s Final Prospectus on Form 424b(4) filed on September 24, 2024, and disclosure in the Issuer’s Current Report on Form 8-K filed on September 25, 2024.

     

    (3)   The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

     

     
     

     

     

     

    CUSIP No.  28622K 203   13G   Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer:

     

    Elevai Labs Inc.

     

     

    (b)

     

    Address of Issuer’s Principal Executive Offices:

     

    120 Newport Center Drive, Suite 250

    Newport Beach, CA 92660

     

    Item 2.

     

    (a)  Name of Person Filing:
       
      L1 Capital Global Opportunities Master Fund, Ltd.
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    161A Shedden Road, 1 Artillery Court

    PO Box 10085

    Grand Cayman, Cayman Islands KY1-1001

       
    (c) Citizenship:
       
      Cayman Islands
       
    (d) Title of Class of Securities:
       
      Common Stock, par value $0.0001 per share
       
    (e)  CUSIP Number:
       
      28622K 203

     

    Item 3.

     

    Not applicable.

     

     

     

     

     
     

     

     

     

     

     
    CUSIP No. 28622K 203   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    (a)–(c)   The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

        The percentage set forth on Row (11) of the cover page for the reporting person is based on 29,704,614 shares of Common Stock outstanding upon the closing of an offering based upon the pre-offering shares outstanding as disclosed in the Issuer’s Final Prospectus on Form 424b(4) filed on September 24, 2024, and disclosure in the Issuer’s Current Report on Form 8-K filed on September 25, 2024.  

     

        David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer’s securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     

     

     

     

     

    CUSIP No.  28622K 203   13G   Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:    L1 Capital Global Opportunities Master Fund, Ltd.
         
    October 1, 2024 By:  /s/ David Feldman
        David Feldman, Director

     

     

    Get the next $ELAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

      NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), today announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic. The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosciences' MitoNova™, provided valuable insights into EL-22's proposed mechanism of action and will help guide further exploration into its potential to address critical unmet needs in muscle-wasting co

      5/22/25 8:16:33 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our") today announced that it has filed its Quarterly Report on Form 10-Q ("Quarterly Report") for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission ("SEC"). The Quarterly Report is available on the SEC's website at www.sec.gov under the company's filings, as well as on the Company's investor relations website. Management believes the Company is well-capitalized, with a strong balance sheet and a clearly defined business focus. Through its operating subsidiaries, the Company is advancing its strategic growth priorities and ac

      5/14/25 4:30:00 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (NASDAQ:TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025.

      5/14/25 8:00:00 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    SEC Filings

    See more
    • PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      5/16/25 2:58:06 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by PMGC Holdings Inc.

      10-Q - PMGC Holdings Inc. (0001840563) (Filer)

      5/14/25 4:04:34 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      5/13/25 4:50:52 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:52:32 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

      3/A - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:51:28 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:47:45 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Financials

    Live finance-specific insights

    See more
    • Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

      Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

      5/1/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    See more
    • PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

      NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

      2/27/25 8:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

      Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

      7/30/24 9:00:26 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

      NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

      6/14/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      11/14/24 5:53:26 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/2/24 4:01:03 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/1/24 4:01:02 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care